Substantial Reduction of Hereditary Angioedema Attack Symptom Burden in the Sebetralstat Phase 3 KONFIDENT Trial

¹AARA Research Center, Dallas, TX, USA; ²Amsterdam University of Cincinnati College of Medical Center, University of Amsterdam, Amsterdam, Amsterdam, Amsterdam, Netherlands; ³University of California, San Diego, La Jolla, CA, USA ¹

Background

- Early treatment has been shown to lead to a shorter attack duration and reduces the risk for progression¹⁻⁵
- On-demand therapies require injections and are associated with delays, which may lead to progression and thereby increased symptom burden^{3, 6-9}
- Sebetralstat, an investigational oral plasma kallikrein inhibitor, was studied in the phase 3 KONFIDENT trial (NCT05259917)^{10,11}
- Despite early treatment of most attacks (median time to treatment, 41 minutes [IQR, 6-140]), >50% of attacks progressed to a rating of "Moderate" to "Very Severe" on the Patient Global Impression of Severity (PGI-S) scale prior to treatment¹

Objective

This post hoc analysis evaluated the impact of sebetralstat on attacks that had progressed in severity prior to treatment

Methods

Trial Design

- The phase 3 KONFIDENT trial was a double-blind, randomized, placebo-controlled, 3-way crossover trial¹¹
- Adults and adolescents (≥12 years) with HAE-C1INH and \geq 2 documented attacks within 3 months were randomly assigned to 1 of 6 treatment sequences in which 3 eligible attacks were treated with 1 to 2 doses of sebetralstat 300 mg. sebetralstat 600 mg, or placebo⁶
- All attack locations and severity levels were included except for laryngeal attacks that were considered severe at onset
- PGI-S ratings from "None" to "Very Severe" were recorded at time of treatment and every 0.5 hours during the first 4 hours after first taking the trial agent, every hour from 5 to 12 hours, and every 2 hours from 14 to 24 hours

Statistical Analysis

• Time to substantial reduction of symptom burden within 12 hours was defined as time to a decrease in PGI-S rating to "Mild" for 2 consecutive time points within 12 hours for attacks that had reached the rating of "Moderate" to "Very Severe" prior to treatment (baseline)

- "Moderate" or worse attacks at baseline were right-censored at 12 hours if they did not reach PGI-S rating of "Mild" or lower (2 time points in a row). Attacks were treated as right-censored at 0 hour if a time-to-event result could not be derived

 Conventional treatment administration was censored to the end of analysis window

A Se _____ Bľ Ra

С

BMI, body mass index; HAE-C1INH, hereditary angioedema due to deficiency or dysfunction of the C1 inhibitor; IQR, interquartile range; LTP, long-term prophylaxis ^aOf the 24 patients receiving LTP, 10 (42%) received berotralstat, 8 (33%) received lanadelumab, and 7 (29%) received C1INH.

B

IQR, interquartile range; n, number of attacks; N/A, not applicable; PGI-S, Patient Global Impression of Severity. ^aBaseline PGI-S rating and baseline attack location are missing for 2 attacks in the sebetralstat 300-mg group. ^bTwo attacks in the placebo group had a baseline PGI-S category of "None".

William R. Lumry,¹ Danny M. Cohn,² Jonathan A. Bernstein,³ Paul K. Audhya,⁴ James Hao,⁴ Michael D. Smith,⁴ Christopher M. Yea,⁴ Marc A. Riedl⁵

Participants and Attacks

Table 1 Demographics and Disease Characteristics


able 1. Demographics and Disease Characteristics					
	Participants with at least 1 attack with PGI-S "Moderate" or worse at baseline n=84	A partici N=′			
ge, median, years (IQR)	40.0 (25.5-49.0)	39.5 (25			
Sex, female, n (%)	48 (57.1)	66 (6			
MI, median, kg/m² (IQR)	26.51 (22.96-31.83)	26.24 (22.			
Race, n (%) White Asian Black or African American Other Not reported IAE-C1INH type, n (%) Type 1 Type 2	72 (85.7) 5 (6.0) 1 (1.2) 1 (1.2) 5 (6.0) 76 (90.5) 8 (9.5)	92 (8 10 (9 1 (0 1 (0 6 (5 101 (9			
ime since HAE-C1INH iagnosis, median, years (IQR)	12 (6.5-22)	12 (7			
Current treatment regimen, n (%) On-demand only On-demand + LTP ^a	69 (82.1) 15 (17.9)	86 (7 24 (2			

Table 2. Characteristics of Treated Attacks at Baseline

	Attacks rated "Moderate" or worse at baseline			•
	Sebetralstat 300 mg n=49	Sebetralstat 600 mg n=52	Placebo n=46	Α
Baseline PGI-S category, n (%) ^{a,b}				
Mild	N/A	N/A	N/A	1
Moderate	35 (71.4)	34 (65.4)	33 (71.7)	1
Severe/very severe	14 (28.6)	18 (34.6)	13 (28.3)	
Baseline primary pooled attack ocation, n (%)				
Mucosal (abdomen, larynx/throat)	24 (49.0)	25 (48.1)	24 (52.2)	-
Larynx/throat	2 (4.1)	1 (1.9)	2 (4.3)	
Subcutaneous (all others)	25 (51.0)	27 (51.9)	22 (47.8)	-
Time from onset of attack to first Idministration, minutes				
Median	35	79	73	
IQR	7-201	6-180	6-223	

	Sebetralstat 300 mg n=49	Sebetralstat 600 mg n=52	
Number of patients			
Events ^a	34 (69.4)	30 (57.7)	
Time to PGI-S rating of "Mild" for			
attacks rated "Moderate" or worse at baseline, ^b hours			
Nominal <i>P</i> -Value	0.002	0.034	
Median	5.0	5.2	
IQR	1.7->12	2.2->12	

Worse at Baseline



The proportion of participants who experienced substantial reduction of symptom burden within 24 hours was 75.5% with sebetralstat 300 mg, 67.3% with sebetralstat 600 mg, and 54.3% with placebo

and their families, their advocates, and the investigator teams who have supported KONFIDENT and KONFIDENT-S.

KalVista thanks the people living with HAE

Please scan the QR code to view this poster after the presentation at the KalVista Virtual Medical Booth.